Name

Phesgo

Alternate names

None

Primary Site

Breast

Histology

None

Radiation

None

Remarks

6/29/2020 The FDA approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer. Patients should be selected based on an FDA-approved companion diagnostic test.

Note: Pertuzumab and trastuzumab are immunotherapy while hyaluronidase-zzxf is an ancillary drug. Code this regimen as BRM/Immunotherapy.

Drugs for Phesgo

Name

Alternate Names

Omnitarg
Perjeta
R1273

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic agent--tyrosine kinase inhibitor
Humanized monoclonal antibody

NSC Number

900005

Primary Site

Breast

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Pertuzumab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code pertuzumab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.

Perjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.

Coding

This drug should be coded

Name

Alternate Names

KADCYLA
T-DM 1
TDM 1
Trastuzumab-MCC-DM1 antibody conjugate
Trastuzumab-MCC-DM1 Immunoconjugate

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Antibody-drug conjugate

NSC Number

None

Primary Site

Metastatic HER-2 breast cancer

Histology

None

Remarks

May 3, 2019: FDA approved ado-trastuzumab emtansine (KADCYLA) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

February 22, 2013: Kadcyla received FDA approval for the treatment of metastatic HER-2 positive breast cancer in patients that had previously been treated with trastuzumab and a taxane, either separately or in combination.

Coding

This drug should be coded
Glossary